.svg)
________________
Biosimilar development places sustained pressure on clinical supply teams to balance cost containment, product quality, and uninterrupted patient access. Comparator biologics are often scarce, expensive, and highly sensitive to handling and storage conditions. Every supply decision carries downstream implications for compliance, continuity of dosing, and inspection readiness.
From a clinical supply standpoint, success in biosimilar trials depends on having the right level of control, visibility, and flexibility across the entire supply chain. Elosity, Endpoint Clinical’s next‑generation RTSM platform, was designed with these realities in mind, helping sponsors strengthen supply resilience, reduce avoidable waste, and execute with confidence in even the most complex comparator‑dependent studies.
________________
Many RTSM platforms in use today were not built to manage the cost intensity, volatility, or compliance rigor associated with biosimilar programs. Over time, these limitations show up as operational inefficiency, unnecessary waste, and increased inspection exposure.
Legacy systems often provide delayed or incomplete insight into site‑level activity. Without real‑time visibility into inventory status, enrollment dynamics, or handling conditions, supply teams are forced to react after issues occur rather than intervene early
Without timely insight, teams often discover issues after deviations occur, increasing remediation effort and audit exposure.
Accurate forecasting is essential when managing high‑cost comparator biologics. Yet many RTSM platforms operate independently of forecasting tools, requiring manual reconciliation between planning assumptions and actual execution.
This disconnect often leads to:
Biosimilar studies rarely follow a straight line. Enrollment rates fluctuate, sourcing strategies evolve, and regional constraints shift over time. Rigid resupply rules in legacy systems struggle to accommodate this variability, increasing the risk of both stockouts and excess inventory.
Inflexibility typically shows up as:
As sourcing models grow more complex, many RTSM systems fall short in supporting the workflows required for inspection‑ready execution. Gaps in traceability or process control can quickly translate into audit risk.
Examples include limited support for:
________________
Elosity, Endpoint Clinical’s next generation RTSM platform, was purpose‑built to address the operational and compliance challenges of biosimilar supply. From a clinical supply perspective, its value lies in aligning inventory decisions with real study activity, while maintaining the controls regulators expect.
Elosity continuously adapts supply to enrollment, visit schedules, and site performance. By responding to real‑world conditions rather than static forecasts, sponsors can right‑size inventory without compromising availability.
Key capabilities include:
Elosity integrates directly with leading forecasting platforms, enabling continuous replanning as study conditions change. This tight alignment reduces over‑ or under‑supply while improving documentation consistency across systems.
From an operational standpoint, this means:
For sponsors managing multiple biosimilar programs, Elosity supports cross‑study pooling of comparator supply while maintaining full traceability. Participant‑level supply control allows teams to allocate inventory dynamically, protecting continuity of dosing during enrollment shifts or unexpected disruptions.
This flexibility helps:
eloAI provides clinical supply teams with immediate access to operational and compliance‑relevant insights. By surfacing early risk indicators—such as slow‑moving inventory, temperature excursions, or emerging expiry risk—teams can act sooner and with greater confidence.
From a clinical supply standpoint, eloAI supports faster, more proactive decision‑making by helping teams:
________________
Across successful biosimilar programs, consistent themes emerge: strong visibility, disciplined inventory control, and the ability to adapt quickly. Elosity operationalizes these best practices by embedding them directly into RTSM workflows, enabling inspection‑ready execution at scale.
Common strategies supported by Elosity include:
________________
When these supply practices are consistently applied, sponsors experience changes that extend beyond reduced waste. From a clinical supply perspective, the impact is felt in day‑to‑day decision‑making, operational stability, and inspection readiness.
With centralized, real time‑ insight into enrollment, inventory, and site activity, sponsors can move from reactive issue management to proactive oversight. Early visibility into emerging risks enables faster intervention, reducing downstream deviations, waste, and operational strain.
What sponsors gain:
By aligning supply more closely to real participant activity, Elosity helps sponsors right size‑ comparator inventory without compromising availability. Smarter planning and adaptive resupply reduce excess while maintaining continuity of dosing, even as enrollment patterns shift or operational conditions change.
Operational and cost benefits:
Across biosimilar programs, these operational improvements translate into consistent, measurable performance gains. By reducing reliance on static assumptions and manual intervention, sponsors are better equipped to manage high cost comparator biologics with greater predictability, speed, and confidence throughout the study lifecycle.
Sponsors typically experience:
________________
Elosity equips biosimilar sponsors with the intelligence and flexibility required to manage high‑cost comparator biologics responsibly. By unifying real‑time insights, forecasting, and adaptive supply strategies, it supports more resilient, compliant, and efficient study execution across the biosimilar lifecycle.
________________
Explore how Elosity can help you reduce waste, protect continuity, and execute with confidence.
https://www.endpointclinical.com/request-a-demo
Smarter Supply. Less Waste. Greater Control.
A Next Generation Approach to Study Design and Delivery
Agentic AI as a Catalyst for Clinical Innovation
